Summary
Introduction:
This text provides an analysis of the use of bacteriophage therapy as a treatment for antibiotic-resistant pneumonia, as well as a warning about the potential harm of high nicotine content in electronic cigarettes.
Key Points:
* Bacteriophage therapy has shown potential in treating antibiotic-resistant pneumonia, but it is not without its challenges. Intravenous administration did not result in eradication of MRSa in an experimental model.
* Phage therapy can stimulate the immune system and neutralizing antibodies are common, which may blunt its effectiveness. aerosolization may be a preferred route of administration for pneumonia treatment in critically ill patients.
* Further research is needed to determine the true benefits of routine phage treatment for antibiotic-resistant pneumonia.
* high nicotine content in electronic cigarettes can disrupt mucociliary clearance, a crucial defense mechanism of the lung, and lead to mucus abnormalities.
* E-cigarette smoking is harmful to the airways and can lead to chronic obstructive pulmonary disease.
* The nicotine concentration in e-cigarettes is dependent and can therefore be more harmful to the airways.
* In vivo studies in sheep showed that e-cigarette liquid with 15-20mg/ml nicotine diminished tracheal mucus velocity by approximately half compared to e-cigarette liquid with 10mg nicotine or e-cigarette vapor with no nicotine.
Main Message:
The text highlights the potential of bacteriophage therapy as a treatment for antibiotic-resistant pneumonia, but also emphasizes the need for further research to determine its true benefits. additionally, it warns of the dangers of high nicotine content in electronic cigarettes and its harmful effects on the airways. It is crucial to consider the concentration of nicotine in e-cigarettes and its potential impact on lung health.
Citation
Kesimer M. another Warning Sign: high Nicotine Content in Electronic Cigarettes Disrupts Mucociliary Clearance, the Essential Defense Mechanism of the Lung. american journal of respiratory and critical care medicine. 2019;200(9):1082-1084. doi:10.1164/rccm.201905-1080ED
